Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Portfolio Question · S5O-04353 · Session 5

What action it is taking to maintain the delivery of drug and alcohol recovery services, in light of the impact of the COVID-19 outbreak.

Answered Asked by Emma Harper SNP Lodged 20 May 2020

The question

To ask the Scottish Government what action it is taking to maintain the delivery of drug and alcohol recovery services, in light of the impact of the COVID-19 outbreak.

The answer

Answered by Joe FitzPatrick on 28 May 2020

In these unprecedented circumstances we expect Alcohol and Drug Partnerships to do all they can to keep the people who rely on their services as safe as is possible.
Options for online and phone support for people in recovery have been developed during the current pandemic. Fellowship and SMART recovery meetings are being offered online. Many ADPs are reporting locally-based recovery support provision through WhatsApp, phone and online groups.
Scotland’s Interim Chief Medical Officer Dr Gregor Smith and I wrote to health boards and Integration Joint Boards on 16 April to ensure the need for continuation of care for this vulnerable group of people is prioritised.
I also wrote a letter with the Chief Pharmaceutical Officer and the Chair of the Drug Death Taskforce, which issued on 12 May to all Directors of Pharmacy and Community Pharmacy Scotland to emphasise the importance of the continued delivery of Opioid Substitution Therapy (OST) during the current period.
I announced on 1 May , a package of 3 measures to provide new support and treatment for those affected by drug use during the COVID-19 pandemic:£1.9 million to support people in prison on prescribed Opiate Substitution Treatment (OST) to switch to a new longer-acting form called Buvidal;£150,000 for residential rehab to people leaving prison to support their recovery and reduce pressure on local services.Widening the availability of overdose reversal drug naloxone.

In the Official Report

No contribution in the Official Report cites S5O-04353 by reference.